RegulatoryJun 8, 2026, 09:11 AM
NeuroSense meets Health Canada on PrimeC ALS regulatory pathway
AI Summary
NeuroSense Therapeutics Ltd. announced a constructive meeting with Health Canada concerning the regulatory pathways for PrimeC, its treatment for amyotrophic lateral sclerosis (ALS). The company presented additional data to support a New Drug Submission (NDS), focusing on its proposed NDS strategy and supporting clinical, biomarker, and long-term outcome data. An official response from Health Canada is anticipated in the third quarter of this year.
Key Highlights
- NeuroSense Therapeutics held a constructive meeting with Health Canada regarding PrimeC for ALS.
- Discussion focused on potential regulatory pathways for PrimeC.
- Company presented additional data to support a New Drug Submission (NDS).
- Proposed NDS strategy, clinical, biomarker, and long-term outcome data were discussed.
- Official response from Health Canada is expected in the third quarter of this year.
Price Impact
More from NRSN